EDAP TMS S.A Retained Earnings (Accumulated Deficit) 2010-2024 | EDAP
EDAP TMS S.A retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
| EDAP TMS S.A Annual Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2024 | $-89 |
| 2023 | $-69 |
| 2022 | $-45 |
| 2021 | $-47 |
| 2020 | $-46 |
| 2019 | $-43 |
| 2018 | $-47 |
| 2017 | $-45 |
| 2016 | $-43 |
| 2015 | $-47 |
| 2014 | $-55 |
| 2013 | $-54 |
| 2012 | $-46 |
| 2011 | $-39 |
| 2010 | $-36 |
| 2009 | $-20 |
| EDAP TMS S.A Quarterly Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2024-12-31 | $-89 |
| 2024-09-30 | |
| 2024-06-30 | |
| 2024-03-31 | |
| 2023-12-31 | |
| 2023-09-30 | |
| 2023-06-30 | |
| 2023-03-31 | |
| 2022-12-31 | |
| 2022-09-30 | |
| 2022-06-30 | |
| 2022-03-31 | |
| 2021-12-31 | |
| 2021-09-30 | |
| 2021-06-30 | |
| 2021-03-31 | |
| 2020-12-31 | |
| 2020-09-30 | |
| 2020-06-30 | |
| 2020-03-31 | |
| 2019-12-31 | $-43 |
| 2019-09-30 | |
| 2019-03-31 | |
| 2018-12-31 | $-47 |
| 2018-09-30 | |
| 2018-06-30 | $-48 |
| 2018-03-31 | |
| 2017-12-31 | $-45 |
| 2017-09-30 | |
| 2017-06-30 | $-43 |
| 2017-03-31 | |
| 2016-12-31 | $-43 |
| 2016-09-30 | |
| 2016-06-30 | $-44 |
| 2016-03-31 | |
| 2015-12-31 | $-47 |
| 2015-09-30 | |
| 2015-06-30 | $-48 |
| 2015-03-31 | |
| 2014-12-31 | $-55 |
| 2014-09-30 | |
| 2014-06-30 | $-62 |
| 2014-03-31 | |
| 2013-12-31 | $-54 |
| 2013-09-30 | |
| 2013-06-30 | $-52 |
| 2013-03-31 | |
| 2012-12-31 | $-46 |
| 2012-09-30 | |
| 2012-06-30 | |
| 2012-03-31 | |
| 2011-12-31 | $-39 |
| 2011-09-30 | |
| 2011-06-30 | $-41 |
| 2011-03-31 | |
| 2010-12-31 | $-36 |
| 2010-09-30 | |
| 2010-06-30 | $-23 |
| 2010-03-31 | |
| 2009-12-31 | $-20 |
| 2009-09-30 | |
| 2009-06-30 | $-14 |
| 2009-03-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.080B | $0.069B |
| EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. | |||